Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vir Biotechnology Inc V.VIR


Primary Symbol: VIR

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.


NDAQ:VIR - Post by User

Comment by sarahturner2022on Jun 06, 2021 7:22pm
165 Views
Post# 33338103

RE:RE:Good company

RE:RE:Good company

- They grow maybe 5% of the cannabis they sell.

- The facility is covered with powder mildew

- They blend cannabis from other grow partners.

- They jar products that arent actually what they say they are

- The jars arent sealed thats why the weed is dry and the bovedas are always dry

- They import low grade cannabis in and flip it for large profits and name it something else

- The MAC-1 is blended from different grow partners thats why EVERY nug tastes different

- The CEO Jarrett Malnarich has been fudging the financials since he was appointed.

- The place is a PONZI scheme


This company is fighting just to pay the payroll and keep the lights on and they will lie to investors until the very end.  My friends who trim for them are already looking for new jobs.

They will be bust in 6 months
<< Previous
Bullboard Posts
Next >>